Yr Athro Howard Kynaston

2024

• Parker, C. C. et al. 2024. Randomised trial of no, short-term, or long-term androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy: results from the three-way comparison of RADICALS-HD (NCT00541047). European Urology 86(5), pp. 422-430. (10.1016/j.eururo.2024.07.026)
• Parker, C. et al. 2024. Timing of Radiotherapy (RT) after Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047]. Annals of Oncology 35(7), pp. 656-666. (10.1016/j.annonc.2024.03.010)
• Turnham, D. J. et al. 2024. Development and characterisation of a new patient-derived Xenograft model of AR-negative metastatic asctration-resistant prostate cancer. Cells 13(8), article number: 673. (10.3390/cells13080673)

2023

• Joharatnam-Hogan, N. et al. 2023. Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial. British Journal of Cancer 129(4), pp. 706-720. (10.1038/s41416-023-02310-1)
• Hamdy, F. C. et al. 2023. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine 388, pp. 1547-1558. (10.1056/NEJMoa2214122)
• Macnair, A. et al. 2023. Healthcare systems data in the context of clinical trials ? A comparison of cardiovascular data from a clinical trial dataset with routinely collected data. Contemporary Clinical Trials 128, article number: 107162. (10.1016/j.cct.2023.107162)
• Donovan, J. L. et al. 2023. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evidence 2, article number: 4. (10.1056/EVIDoa2300018)

2022

• Minto, T. et al. 2022. Safety of maintaining elective and emergency surgery during the COVID-19 pandemic with the introduction of a Protected Elective Surgical Unit (PESU): A cross-specialty evaluation of 30-day outcomes in 9,925 patients undergoing surgery in a University Health Board. Surgery Open Science 10, pp. 168-173. (10.1016/j.sopen.2022.09.005)

2021

• Shephard, A. P. et al. 2021. Stroma-derived extracellular vesicle mRNA signatures inform histological nature of prostate cancer. Journal of Extracellular Vesicles 10(12), article number: e12150. (10.1002/jev2.12150)
• Tan, W. S. et al. 2021. Major urological cancer surgery for patients is safe and surgical training should be encouraged during the covid-19 pandemic: a multicentre analysis of 30-day outcomes. European Urology Open Science 25, pp. 39-43. (10.1016/j.euros.2021.01.005)
• Langley, R. E. et al. 2021. Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. Lancet 397(10274), pp. 581-591. (10.1016/S0140-6736(21)00100-8)

2019

• Bullock, N., Simpkin, A., Fowler, S., Varma, M., Kynaston, H. and Narahari, K. 2019. Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry. BMC Urology 19(1), pp. -., article number: 94. (10.1186/s12894-019-0526-9)
• Bullock, N., Serag, H. and Kynaston, H. 2019. Radical open surgery for management of extensive extra-prostatic benign prostatic hyperplasia. Journal of Clinical Urology 12(5), pp. 398-400. (10.1177/2051415818767181)
• Burnell, S. E. A., Spencer-Harty, S., Howarth, S., Bodger, O., Kynaston, H., Morgan, C. and Doak, S. H. 2019. Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer. PLoS ONE 14(8), article number: e0220456. (10.1371/journal.pone.0220456)
• Foley, K., Christian, A., Peaker, J., Marshall, C., Spezi, E., Kynaston, H. and Roberts, S. A. 2019. Cyclo-oxygenase-2 expression is associated with mean standardised uptake value on 18F-fluorodeoxyglucose positron emission tomography in oesophageal adenocarcinoma. British Journal of Radiology 92(1099), article number: 20180668. (10.1259/bjr.20180668)
• Pacey, S. et al. 2019. A study into the pharmacodynamic biomarker effects of olaparib (PARP Inhibitor) ± degarelix (GnRH antagonist) given prior to radical prostatectomy (RP) CANCAP03.. Journal of Clinical Oncology 37(7_supp) (10.1200/JCO.2019.37.7_suppl.35)

2018

• Varma, M., Cochlin, D., Delahunt, B., Kynaston, H., Rees, J., Rous, B. and Narahari, K. 2018. TNM clinical staging of prostate cancer: issues and solutions. BJU International 123(3), pp. 382-384. (10.1111/bju.14589)
• Burnell, S. E. A., Spencer-Harty, S., Howarth, S., Bodger, O., Kynaston, H., Morgan, C. and Doak, S. H. 2018. STEAP2 knockdown reduces the invasive potential of prostate cancer cells. Scientific Reports 8(1), article number: 6252. (10.1038/s41598-018-24655-x)
• Donovan, J. L. et al. 2018. A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology 96, pp. 35-46. (10.1016/j.jclinepi.2017.12.019)

2017

• Jefferies, M. T. et al. 2017. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis. Journal of Pathology 243(4), pp. 442-456. (10.1002/path.4977)
• KandaSwamy, G. V., Bennett, A., Narahari, K., Hughes, O., Rees, J. and Kynaston, H. 2017. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer – results from a large contemporaneous cohort. BJU International 120(5B), pp. E59-E63. (10.1111/bju.13850)
• Jefferies, M. T., Pope, C., Kynaston, H., Clarke, A. R., Martin, R. and Adams, J. 2017. Analysis of fascin-1 in relation to gleason risk classification and nuclear ets-related gene status of human prostate carcinomas: an immunohistochemical study of clinically annotated tumours from the Wales Cancer Bank. Biomarkers in Cancer 9, pp. 1-8. (10.1177/1179299X17710944)

2016

• Gilbert, D. C. et al. 2016. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. BJU International 119(5), pp. 667-675. (10.1111/bju.13687)
• Coyle, C. et al. 2016. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemporary Clinical Trials 51, pp. 56-64. (10.1016/j.cct.2016.10.004)
• Hamdy, F. et al. 2016. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine 375, pp. 1415-1424. (10.1056/NEJMoa1606220)
• Donovan, J. L. et al. 2016. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine 375, pp. 1425-1437. (10.1056/NEJMoa1606221)
• Langley, R. E. et al. 2016. A randomised comparison evaluating changes in bone mineral density in advanced prostate cancer: luteinising hormone-releasing hormone agonists versus transdermal oestradiol. European Urology 69(6), pp. 1016-1025. (10.1016/j.eururo.2015.11.030)
• Weeks, H., Sanders, A., Kynaston, H. and Jiang, W. 2016. The association between WAVE1 and -3 and the ARP2/3 complex in PC 3 cells. Anticancer Research 36(3), pp. 1135-1142.

2015

• Moazzam, M., Ye, L., Sun, P., Kynaston, H. and Jiang, W. G. 2015. Knockdown of WAVE3 impairs HGF induced migration and invasion of prostate cancer cells. Cancer Cell International 15, article number: 51. (10.1186/s12935-015-0203-3)
• Webber, J. P. et al. 2015. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 34(3), pp. 290-302. (10.1038/onc.2013.560)

2014

• Whiteland, H. et al. 2014. A role for STEAP2 in prostate cancer progression. Clinical & Experimental Metastasis 31(8), pp. 909-920. (10.1007/s10585-014-9679-9)
• Aboumarzouk, O. et al. 2014. 670 Emphysematous pyelonephritis: time for a management plan with an evidence based approach. European Urology Supplements 13(1), article number: e670. (10.1016/S1569-9056(14)60660-6)

2013

• Jiang, W. G., Ye, L., Sanders, A. J., Ruge, F., Kynaston, H., Ablin, R. J. and Mason, M. D. 2013. Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain. Journal of Translational Medicine 11, article number: 269. (10.1186/1479-5876-11-269)
• Aboumarzouk, O., Hughes, O., Narahari, K., Drewa, T., Chlosta, P. L. and Kynaston, H. 2013. Safety and feasibility of Laparoscopic Radical Cystectomy for the treatment of bladder cancer. Journal of Endourology 27(9), pp. 1083-1095. (10.1089/end.2013.0084)
• Langley, R. E. et al. 2013. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). The Lancet Oncology 14(4), pp. 306-316. (10.1016/S1470-2045(13)70025-1)

2012

• Williams, R., Shorning, B., Datta, S., Kynaston, H. and Clarke, A. R. 2012. Development and characterisation of a bladder cancer model [Poster]. BJU International 109(S7), pp. 25-25. (10.1111/j.1464-410X.2012.11177.x)
• Shelley, M. D., Jones, G., Cleves, A., Wilt, T. J., Mason, M. D. and Kynaston, H. 2012. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. British Journal of Urology International 109(4), pp. 496-505. (10.1111/j.1464-410X.2011.10880.x)
• Jones, G., Cleves, A., Wilt, T. J., Mason, M. D., Kynaston, H. and Shelley, M. 2012. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database of Systematic Reviews 1, article number: CD009294. (10.1002/14651858.CD009294.pub2)

2011

• Li, J., Ye, L., Kynaston, H. and Jiang, W. G. 2011. Repulsive guidance molecules, novel bone morphogenetic protein co-receptors, are key regulators of the growth and aggressiveness of prostate cancer cells. International Journal of Oncology 40(2), pp. 544-550. (10.3892/ijo.2011.1251)
• Ablin, R. J., Kynaston, H., Mason, M. D. and Jiang, W. G. 2011. Prostate transglutaminase (TGase-4) antagonizes the anti-tumour action of MDA-7/IL-24 in prostate cancer. Journal of Translational Medicine 9, pp. 49-57. (10.1186/1479-5876-9-49)

2010

• Shelley, M. D., Mason, M. D. and Kynaston, H. 2010. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treatment Reviews 36(3), pp. 195-205. (10.1016/j.ctrv.2009.12.005)
• Zhang, N., Sanders, A. J., Ye, L., Kynaston, H. and Jiang, W. 2010. Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro. Anticancer Research 30(1), pp. 87-95.
• Jiang, W. G., Ye, L., Ablin, R. J., Kynaston, H. and Mason, M. D. 2010. The prostate transglutaminase, TGase-4, coordinates with the HGFL/MSP-RON system in stimulating the migration of prostate cancer cells. International Journal of Oncology 37(2), pp. 413-418. (10.3892/ijo_00000689)
• Herman, F., Martin, T. A., Douglas-Jones, A., Kynaston, H. G., Mansel, R. E. and Jiang, W. G. 2010. Expression of the ERM family members (ezrin, radixin and moesin) in breast cancer. Experimental and Therapeutic Medicine 1(1), pp. 153-160. (10.3892/etm_00000025)
• Bokobza, S. M., Ye, L., Kynaston, H. and Jiang, W. G. 2010. Growth and differentiation factor-9 promotes adhesive and motile capacity of prostate cancer cells by up-regulating FAK and Paxillin via Smad dependent pathway. Oncology Reports 24(6), pp. 1653-1659. (10.3892/or_00001030)
• Bokobza, S. M., Ye, L., Kynaston, H. and Jiang, W. G. 2010. GDF-9 promotes the growth of prostate cancer cells by protecting them from apoptosis. Journal of Cellular Physiology 225(2), pp. 529-536. (10.1002/jcp.22235)
• Fernando, H. S., Sanders, A. J., Kynaston, H. and Jiang, W. G. 2010. WAVE3 is associated with invasiveness in prostate cancer cells. Urologic Oncology: Seminars and Original Investigations 28(3), pp. 320-327. (10.1016/j.urolonc.2008.12.022)
• Bokobza, S. M., Ye, L., Kynaston, H. and Jiang, W. G. 2010. Growth and differentiation factor 9 (GDF-9) induces epithelial-mesenchymal transition in prostate cancer cells. Molecular and Cellular Biochemistry 349(1-2), pp. 33-40. (10.1007/s11010-010-0657-5)

2009

• Zhang, N., Sanders, A. J., Ye, L., Kynaston, H. and Jiang, W. G. 2009. Vascular endothelial growth inhibitor, expression in human prostate cancer tissue and the impact on adhesion and migration of prostate cancer cells in vitro. International Journal of Oncology 35(6), pp. 1473-1480. (10.3892/ijo_00000466)
• Ye, L., Kynaston, H. and Jiang, W. G. 2009. Bone Morphogenetic Protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway. The Journal of Urology 181(6), pp. 2749-2759. (10.1016/j.juro.2009.01.098)
• Bokobza, S. M., Ye, L., Kynaston, H., Mansel, R. E. and Jiang, W. G. 2009. Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. Cancer Genomics and Proteomics 6(2), pp. 101-108.
• Fernando, H. S., Kynaston, H. and Jiang, W. G. 2009. WASP and WAVE proteins: vital intrinsic regulators of cell motility and their role in cancer (Review). International Journal of Molecular Medicine 23(2), pp. 141-148. (10.3892/ijmm_00000111)
• Jiang, W. G., Ablin, R. J., Kynaston, H. and Mason, M. D. 2009. The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway. Microvascular Research 77(2), pp. 150-157. (10.1016/j.mvr.2008.09.010)

2008

• van Andel, G. et al. 2008. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer 44(16), pp. 2418-2424. (10.1016/j.ejca.2008.07.030)
• Langley, R. E. et al. 2008. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU International 102(4), pp. 442-445. (10.1111/j.1464-410X.2008.07583.x)
• Hudson, E. et al. 2008. Radiotherapy after radical prostatectomy for adenocarcinoma of the prostate: a UK institutional experience and review of published studies. Clinical Oncology 20(5), pp. 353-357. (10.1016/j.clon.2008.02.008)
• Fernando, H. S., Sanders, A. J., Kynaston, H. and Jiang, W. G. 2008. WAVE1 is Associated with Invasiveness and Growth of Prostate Cancer Cells. The Journal of Urology 180(4), pp. 1515-1521. (10.1016/j.juro.2008.06.004)
• Ye, L., Lewis-Russell, J. M., Sanders, A. J., Kynaston, H. G. and Jiang, W. G. 2008. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. Urologic Oncology: Seminars and Original Investigations 26(2), pp. 190-197. (10.1016/j.urolonc.2007.03.027)
• Ye, L., Kynaston, H. and Jiang, W. G. 2008. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Molecular Cancer Research 6(10), pp. 1594-1606. (10.1158/1541-7786.MCR-08-0171)
• Fernando, H., Sanders, A. J., Jenkins, S., Kynaston, H. and Jiang, W. G. 2008. Wave 3 (Wasp Verprolin-Homologous Protein) 3 is involved in the invasiveness of PC-3 cells [Abstract]. European Urology Supplements 7(3), pp. 173. (10.1016/S1569-9056(08)60406-6)

2007

• Harland, S. J. et al. 2007. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. The Journal of Urology 178(3 pt1), pp. 807-813. (The Journal of Urology)

2002

• Bisson, J. I., Chubb, H. L., Bennett, S., Mason, M. D., Jones, D. and Kynaston, H. G. 2002. The prevalence and predictors of psychological distress in patients with early localized prostate cancer. British Journal of Urology International 90(1), pp. 56-61. (10.1046/j.1464-410X.2002.02806.x)